# Combination of Radiotherapy and Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer: Clinical Progress Advances and Future Directions

## TL;DR

This paper reviews the progress and future directions of combining radiotherapy and immunotherapy for treating advanced non-small cell lung cancer.

## Contribution

The paper systematically reviews the synergy mechanisms and clinical trial advances of radiotherapy and immunotherapy combinations.

## Key findings

- Combining radiotherapy and immunotherapy improves anti-tumor efficacy in unresectable NSCLC.
- The PACIFIC trial established immunotherapy as a standard after chemoradiation.
- Key challenges include optimal timing and managing side effects of combined treatments.

## Abstract

III期非小细胞肺癌（non-small cell lung cancer, NSCLC）约占初诊NSCLC的30%，且绝大多数患者无法手术切除，其不可手术特性使根治性放化疗成为核心治疗手段。近年来，随着免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）成为肺癌领域的研究热点，越来越多的研究表明放疗联合免疫治疗（combination of radiotherapy and immunotherapy, iRT）能通过协同机制显著提升抗肿瘤疗效，PACIFIC研究的突破性进展更确立了同步放化疗后免疫巩固治疗的标准地位。然而，最佳放疗策略、免疫介入时机、不良事件管理和生物标志物探索等问题仍存争议。本综述旨在系统阐述iRT的协同作用机制，梳理不同iRT治疗模式下（同步、巩固、诱导）的临床试验进展，并对当前临床实践中的关键问题与未来研究方向进行深入探讨。

Clinical trials of radiotherapy combined with immunotherapy for unresectable III stage NSCLC been completed

Clinical trials of radiotherapy combined with immunotherapy for unresectable III stage NSCLC ongoing